Hip fractures are a major cause of morbidity and mortality, particularly in elderly patients. Accurate prediction of postoperative mortality is critical for risk stratification and clinical decision-making. Traditional scoring systems, such as the Nottingham Hip Fracture Score, have limitations in capturing complex, non-linear relationships among clinical variables.
This retrospective cohort study aims to develop and validate an artificial intelligence-based model to predict 30-day mortality in patients undergoing hip fracture surgery. Clinical and laboratory data of approximately 1000 patients operated between January 1, 2022 and December 1, 2025 will be extracted from electronic health records. Variables include demographic characteristics, comorbidities, laboratory parameters, perioperative data, and postoperative complications.
The performance of the artificial intelligence model will be evaluated and compared with conventional risk scoring systems. The study seeks to determine whether AI-based approaches can provide improved predictive accuracy for postoperative mortality in hip fracture patients.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Patients who underwent surgical treatment for hip fracture between January 1, 2022 and December 1, 2025 Age ≥18 years Availability of complete demographic, clinical, and laboratory data in the electronic health record system Documented 30-day follow-up or mortality status
Exclusion Criteria:
Patients with malignancy Patients undergoing revision hip surgery Patients with missing or incomplete key clinical or laboratory data required for analysis Patients with unavailable or undocumented 30-day mortality status
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
30-Day Postoperative Mortality
Timeframe: 30 days after surgery and 1 year later
Trial details
NCT IDNCT07495527
SponsorDr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital